title: Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones.
abstract: OBJECTIVE
  To report a case of spontaneous resolution of diabetic maculopathy with cystoid macular oedema in a diabetic patient after discontinuation of rosiglitazone, documented with serial ocular computed tomography (OCT) images.
  
  
  METHODS
  A 59-year-old male with a 6-year history of well-controlled diabetes mellitus presented with reduced visual acuity (VA) attributed to clinically significant macular oedema (CSMO). The patient had been started on rosiglitazone 8 months previously. Glitazone treatment was stopped and the patient prospectively followed up.
  
  
  RESULTS
  The patient demonstrated CSMO on OCT at presentation. Three months after cessation of rosiglitazone, CSMO had completely resolved and VA improved. Resolution of CSMO was confirmed on OCT examination. The patient required no interventional treatment, i.e. no laser or intravitreal therapy, for his CSMO.
  
  
  CONCLUSIONS
  To the best of our knowledge, this is the first case to document spontaneous resolution of CSMO and improvement in VA on discontinuation of a glitazone. Glitazones have a definitive role in the management of diabetic patients and ophthalmologists and physicians should both be aware that there may be an association with weight gain, peripheral oedema and CSMO. We recommend that ophthalmologists consider discontinuing glitazones in consultation with the diabetologist before embarking on interventional management such as laser or intravitreal injections.
authors.affiliation: St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. stliazos@hotmail.com
authors.forename: E
authors.initials: E
authors.lastname: Liazos
authors.forename: D M
authors.initials: DM
authors.lastname: Broadbent
authors.forename: N
authors.initials: N
authors.lastname: Beare
authors.forename: N
authors.initials: N
authors.lastname: Kumar
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008269:Macular Edema / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014792:Visual Acuity
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone